Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats-Reference-Cited by-同舟云学术

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats

Published:2019-06 Issue:3 Volume:13 Page:398-408
ISSN:2095-0217
Container-title:Frontiers of Medicine
language:en
Short-container-title:Front. Med.

Author:

Zhang Ruoxi,Chen Jing,Liu Diangang,Wang Yu

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1007/s11684-019-0689-5/fulltext.html

Reference38 articles.

1. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005; 6(4 Suppl 2): S125–S130

2. McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int 2018; 12(Suppl 1):11–23

3. Vilaseca M, García-Calderó H, Lafoz E, García-Irigoyen O, Avila MA, Reverter JC, Bosch J, Hernández-Gea V, Gracia-Sancho J, García-Pagán JC. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology 2017; 65(6): 2031–2044

4. Vilaseca M, García-Calderó H, Lafoz E, Ruart M, López-Sanjurjo CI, Murphy MP, Deulofeu R, Bosch J, Hernández-Gea V, Gracia-Sancho J, García-Pagán JC. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver Int 2017; 37(7): 1002–1012

5. Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998; 27(2): 472–480

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases;Sinusoidal Cells in Liver Diseases;2024

2. Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response;Liver International;2023-07-13

3. Emerging Therapeutic Targets for Portal Hypertension;Current Hepatology Reports;2023-02-11

4. Current and investigational drugs in early clinical development for portal hypertension;Frontiers in Medicine;2022-10-10

5. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy;JHEP Reports;2021-08